Trial Profile
A Phase 0 Pharmacodynamic Study of Dasatinib in Women With Newly Diagnosed Endometrial Cancer
Status:
Completed
Phase of Trial:
Phase 0
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Dasatinib (Primary)
- Indications Adenocarcinoma; Endometrial cancer
- Focus Pharmacodynamics; Proof of concept
- 07 Jun 2016 Results presented at the 52nd Annual Meeting of the American Society of Clinical Oncology
- 11 May 2016 Status changed from active, no longer recruiting to completed.
- 26 May 2015 Planned primary completion date changed from 1 Dec 2014 to 1 May 2015 as reported by ClinicalTrials.gov